Group 1 - The Hong Kong pharmaceutical sector is experiencing adjustments in Q4 2025 due to overseas liquidity expectations and market style rotation, leading to a weakening of concerns regarding the bubble in innovative drugs [1] - After the New Year holiday, there has been a resurgence of interest in AI healthcare and brain-computer interface sectors, with funds refocusing on Hong Kong pharmaceuticals, resulting in the Hang Seng Pharmaceutical ETF (159892) achieving a year-to-date increase of over 13% [1] - From a policy perspective, the new medical insurance directory and commercial insurance directory officially took effect on January 1, which is expected to boost the volume of selected drugs; the launch of the Chinese drug price registration system supports the domestic commercialization and international expansion of innovative drugs [1]
港股医药行情火爆！聚焦创新药、AI医疗、脑机接口三大主线
Sou Hu Cai Jing·2026-01-08 02:38